Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC
Written by
Cancer Network
Published
0
comments
0
min
Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.